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Purpose: To evaluate overall survival (OS), progression-free survival (PFS), loco-regional
recurrence (LRR), and toxicities for early breast-cancer patients with one to three positive
axillary lymph nodes, by the addition of radiotherapy to adjuvant chemotherapy.
Patients and methods: Patients were eligible for enrollment into the study if they had
pathologically proven stages II breast cancer, with one to three positive axillary lymph
nodes. Patients were assigned to one of the two groups; Group 1; adjuvant chemotherapy
then radiotherapy, and group 2; adjuvant chemotherapy only.
Results: Between September 2008 and August 2014, 75 patients were enrolled. Forty
patients group 1, and 35 group 2.The 4-year OS for group 1, and two were 77.5 and 71.4%,
respectively.The 4-year PFS for group 1 and 2 were 72.5 and 60%, respectively. During the
54months follow-up period, 11 patients from group 1 had recurrence (three locoregional,
seven metastatic, and one both), and 14 patients from group 2 had recurrence (seven
locoregional, three metastatic, and four both). The distant metastasis rate was the same
in the two groups. However, the metastasis sites were different in the two groups.
Conclusion:The addition of radiotherapy in stage II breast cancer with one to three posi-
tive lymph nodes improved the PFS, and LRR. Radiotherapy improved OS in patients with
high-risk features.
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INTRODUCTION
Breast cancer is the most frequent malignant tumor in women
worldwide. In Egypt, it is the most common cancer among
women, representing 18.9% of total cancer cases. More than 50%
of patients present as early stages, thanks to advances that had
recently made in the strategies of screening and early detection. A
study by Salem et al. (1), showed that, in Egypt, 11% of patients
presented as stage I, 30% stage II, 33% stage III, and 26% stage
IV (1, 2).
Radiation therapy (RT) is frequently recommended for patients
with early breast cancer who had undergone mastectomy. Guide-
lines from the American Society of Clinical Oncology (ASCO),
the National Comprehensive Cancer Network (NCCN), and the
American College of Radiology (ACR), all recommend for post-
mastectomy RT for patients with four positive lymph nodes.
However, these patients account for only a minority of node-
positive disease. Unfortunately, all the three guidelines reported
that insufficient evidence still exist to make any evidence-based
post-mastectomy recommendations for patients with one to three
positive nodes (2–5).
Considering RT in early breast cancer with one to three positive
axillary lymph nodes remains unclear. Till recently, studies were
unable to provide definite answers regarding this controversial
issue (6–8).
STUDY OBJECTIVES
To evaluate the overall survival (OS), progression-free survival
(PFS), loco-regional recurrence (LRR), and toxicities for early
breast-cancer patients with one to three positive axillary lymph
nodes, who underwent mastectomy, and axillary lymph node
dissection, followed by either adjuvant chemotherapy and radio-
therapy, or only adjuvant chemotherapy.
The primary end point was survivals benefits (PFS and OS).
The secondary end points were LRR and toxicities.
MATERIALS AND METHODS
INCLUSION CRITERIA
Female patients were eligible for enrollment into the study if they
had pathologically proven breast cancer with one to three positive
axillary lymph nodes on pathological examination. Status post
mastectomy and axillary lymph node dissection. Patients should
have stages II breast cancer (T1N1, T0N1, T2N1), with tumor size
≤5cm (pT1-2).
Further, for enrollment, patients should be between 17 and
65 years. Performance state had to be from 0 to 2 (ECOG). Patients
should have adequate hematological, renal, and liver functions.
Written informed consent from patients needed before proceed-
ing in the trial. Female patients of childbearing potential must have
a negative pregnancy test (serum β-HCG); and both the patient
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and her husband must employ effective contraceptive measures
prior to the start of therapy until 4 weeks after the last dose of
chemotherapy. Hormone receptor status has to be either ER or
PR+ ve, with HER 2 neu either positive or negative. Adjuvant
chemotherapy should include anthracycline. Additionally, patients
must have no concurrent malignancy.
Settings: The study was run in 2 educational institutes in Egypt;
Ain Shams University Hospital, and Ismailia oncology teaching
hospital.
Study design: Patients were assigned to one of the following
groups;
Group 1: patients underwent adjuvant chemotherapy then
radiotherapy,
Group 2: patients underwent adjuvant chemotherapy only.
RADIOTHERAPY
Radiotherapy was delivered by 3D conformal radiotherapy (CRT).
Positioning: The patient was placed supine with both arms above
her head. Immobilization was maintained by the commercially
available devices.
Simulation: Simulation was done using CT simulation technique.
Surgery scar, borders, and reference points were marked with
radio-opaque wire before CT scanning. Clinical target volume
(CTV), (OAR) definition as the following (Figure 1);
CTV was defined as the excision cavity plus 1.5 cm free resection
margin.
The definitions of chest wall borders were guided by the
following landmarks;
- Cranial: the caudal border of the clavicle head,
- Caudal: clinical reference, loss of CT apparent contralateral
breast,
- Anterior: skin,
- Posterior: deep fascia,
- Lateral: clinical reference, mid axillary line,
- Medial: clinical reference.
The definitions of supraclavicular field borders are guided by
the following landmarks;
- Cranial: inferior border of cricoid cartilage,
- Caudal: caudal edge of clavicular head/junction of brachio-
cephalic axillary veins,
- Anterior: sterocleidomastoid muscle,
- Posterior: anterior edge of the scalene muscle,
- Lateral: cranially: lateral edge of sterocleidomastoid muscle, and
caudally: the first rib-clavicle junction,
- Medial: excludes thyroid and trachea.
FIGURE 1 | CT planning for a patient in our study showing the field arrangements, doses.
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Planning target volume (PTV) was equal the CTV plus 0.5–
1 cm. The target was considered to be appropriately treated if the
PTV was enclosed within the 95–105% isodose line.
ORGANS AT RISK
The organs at risk (OAR) included the heart major blood vessels,
ipsilateral, contolateral lungs, contralateral breast, cervical cord,
and brachial plexus. Radiotherapy planning had to be adjusted to
avoid OAR (9).
Field arrangement
Radiotherapy was delivered to the chest wall, and the supraclavic-
ular fields using the same isocenter (mono-isocentric technique).
Chest wall irradiation was done using two tangential fields, with
the use of wedges as indicated. Multi-leaf collimator applied for
optimally adjusting the therapeutic field to the tumor area. Supr-
aclavicular Field irradiation was done by an anterior oblique
field angled slightly away from the spinal cord. A humeral head
block was added to block the humeral head and acromioclavicular
joint.
Dose
The intended dose was 50 Gy, given in 25 fractions over a period
of 5 weeks by conventional fractionation (2Gy/fraction).
RT machine was Linear accelerator 6-9 MV (10, 11).
After RT, all the patients were put on hormonal therapy.
Additionally, those who had HER2+ ve disease continued on
trastuzumab for 1 year.
FOLLOW-UP
After finish of the treatment protocol, patients were followed-up
according to the NCCN recommendations; by regular clinic visits
every 4–6 months for the first 5 years, then annually thereafter. In
each visit, patients were evaluated by history, physical examination.
Annual X ray mammography, annual gynecological assessment for
those on tamoxifin, and frequent DEXA scanning for those on
aromatase inhibitors (5).
TOXICITY
Toxic effects were graded according to the National Cancer Insti-
tute Common Toxicity Criteria, version 2.0. Early toxicities were
defined as toxicities that occurred during treatment till 8 weeks
post radiotherapy. Late toxicities referred to those occurred
>8 weeks after finish of treatment protocol (12).
STATISTICAL ANALYSIS
All calculations were carried out using prism-6 software for win-
dows. All analyses were carried by intention to treat. Mean and
median values were used for the description of continuous data.
For comparison between the two group characters, t -test, and p-
value were used. OS and PFS for each arm were analyzed by the
Kaplan–Meier method. Further, they were compared using the log
rank and Wilcoxon tests.
The univariate cox hazard analysis was applied to evaluate
the effect of pre-specified prognostic factors including age,
performance state, histopathological type, grade, stage, HER sta-
tus, numbers of positive lymph nodes, and invasion on OS, PFS,
recurrence, and deaths.
p-Value was significant at ≤0.05. Further to that, the study
power was checked using SPSS-19 software.
Overall survival was measured from the time of randomization
till death or the last follow-up visit. PFS was measured from the
time of randomization till relapse, recurrence, or the last follow-up
visit. LRR was defined as reappearance of local or regional tumor
(in the chest wall, axilla, supraclavicular, or infraclavicular area)
without distant metastases.
RESULTS
Between September 2008 and August 2014, 75 patients were
enrolled in the current study. Forty patients were assigned to
treatment group 1, and 35 patients were assigned to group 2. All
the 75 patients fulfilled our eligibility criteria. The mean age was
52.4 years (range 29–65 years). The median performance status
was 0 (range 0–2). All the 75 patients had stage II (4 T0N1, 29
T1N1, 42 T2N1) (5%, 39 and 56%, respectively) (Table 1).
TREATMENT PROTOCOL
All the 75 patients underwent modified radical mastectomy, with
axillary lymph node dissection (level I, II). Axillary lymph node
dissection was done after sentinel lymph node examination in 50
patients by frozen section during the operation. A median of 10
lymph nodes were removed (range 5–16).
Following mastectomy, all our patients underwent adjuvant
chemotherapy at mean time of 4 weeks. Chemotherapy regimes
used included FAC (12 patients of group 1 and 13 patients group
2), AC (6 patients of group 1 and 2 patients group 2), and
sequential AC, taxene (20 patients of group 1 and 20 patients
group 2).
Additionally, two patients of group 1 received adjuvant CMF
after the first cycle of FAC. The first patient developed prolonged
febrile neutropenia grade IV, prolonged grade IV vomiting after
cycle 1, and the second patient, who had history of rheumatic
mitral regurgitation, developed low ejection fraction (EF) after
cycle 1.
Further, 2 patients received adjuvant trastuzumab for HER-2
neu positive status (one group 1, one group 2).
RADIOTHERAPY
Radiotherapy was initiated at mean time of 2 weeks (range 2–
3 weeks) after the last chemotherapy cycle for group 1 patients.
Radiotherapy was given to all patients by 3D CRT, with CT sim-
ulation. The median RT dose was 50 Gy, in 25 fractions for all
patients of group 1 (2Gy/fraction) (range 45–50 Gy).
Following adjuvant treatment, the two patients with HER+ ve
disease continued the full year of adjuvant Trastuzumab. Adjuvant
hormonal therapy was given to our patients in the form of tamox-
ifin (25 patients) and sequential tamoxifin, armatase inhibitors (50
patients).
SURVIVAL DATA
The median follow-up period was 54 (range 50–60 months).
The 4-year OS for group 1 and 2 were 77.5 and 71.4%, respec-
tively (Figure 2). During the follow-up period, nine patients died
from group 1 (8 cancer recurrence, and 1 cardiovascular cause),
and 10 patients from group 2 died (9 cancer recurrence and 1
pulmonary embolism).
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Table 1 | Patients and diseases characteristics of each treatment group.
Characteristics Group 1 Group 2 P -value
Number % Number %
Age
17–<40 1 2.5% 0 0% –
40–49 12 30% 11 31% 0.2
50–60 17 42.5% 14 40% 0.1
61–65 10 25% 10 29% 0.3
Mean age 52 – 53 –
Performance status (ecog)
0 20 50% 17 48.5% 0.2
1 15 37.5% 14 40% 0.1
2 5 12.5% 4 11.5% 0.1
Performance status (median) 0 – 0 –
Pathological classification
Ductal 29 72.5% 26 74% 0.09
Lobular 11 27.5% 9 26% 0.06
Other 0 0
Pathological grade
1 5 12.5% 6 17% 0.1
2 15 37.5% 19 54% 0.09
3 20 50% 10 28.5% 0.03
Grade mean, median 2.3, 3 – 2, 2 –
Tumor stage
pT0N1 2 5% 2 6% 0.2
pT1N1 10 25% 19 54% 0.05
pT2N1 28 70% 14 40% 0.01
Tumor stage median pT2N1 pT1N1
Lymph node number
1 4 10% 7 20% 0.2
2 16 40% 15 42% 0.2
3 20 50% 13 37% 0.06
Lymph node number median 3 2
Her 2 neu
Positive 2 5% 2 6% 0.1
Negative 38 95% 33 94% 0.09
Invasion
Lymphatic 15 37.5% 12 34% 0.1
Vascular/Peri-nural 10 25% 9 25% 0.2
The 4-year PFS for group 1 and 2 were 72.5 and 60% respectively
(Figure 3).
For subgroup analysis, Tables 2 and 3 showed the 4-year OS,
4-year PFS categorized by the prognostic features.
During the 54 months follow-up period,11 patients from group
1 developed breast-cancer recurrence (3 locoregional, 7 metasta-
tic, and 1 both), and 14 patients from group 2 had recurrence (7
locoregional, 3 metastatic, and 4 both) (Tables 4 and 5).
The distant metastasis rate was the same in the two groups
(20% in both). However, the metastasis sites were different in the
two groups. The sites of distant metastasis for group 1 were bone,
FIGURE 2 |The 4-year OS for the study groups – p-value: 0.2, chi
square 1.29.
FIGURE 3 |The 4-year PFS for the study groups – p-value 0.03, chi
square 4.28.
liver, and lung, respectively (55, 30, and 15%, respectively). The
sites of distant metastasis for group 2 were liver, lung, and bone,
respectively (60, 25, and 15%, respectively).
TOXICITIES
Early toxicity
Radiotherapy side effects. Radiotherapy delay happened in four
patients (10%). The mean delay time was 1 week (range 5–
14 days). No patient discontinued from RT for side effect. No
deaths occurred related to treatment (Table 7).
Late toxicities
For group 1. During the 54 months follow-up period, four
patients from group 1 developed lymphedema grade I–II (10%).
No patient developed lung toxicity or brachial plexopathy. One
patient from group 1 died from congestive cardiac failure at
50 months, to note that patient was known to have long history
of rheumatic mitral regurgitation, and her EF was 45% before
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Table 2 |The 4-year OS for each treatment group categorized by the
prognostic factors.
Group 1% Group 2 % P -value
Age
17–<40 100 – –
40–49 75 72 0.07
50–60 76 78 0.1
61–65 70 60 0.01
Performance status
0 90 88 0.3
1 73 64 0.03
2 40 25 0.01
Pathological classification
Ductal 82 76 0.04
Lobular 63 55 0.04
Pathological grade
1 100 83 0.03
2 73 78 0.3
3 75 50 0.009
Tumor stage
pT0N1 100 50 0.001
pT1N1 80 73 0.06
pT2N1 75 71 0.2
Lymph node number
1 75.5 71 0.2
2 87 78 0.04
3 70 64 0.03
Her 2 neu
Positive 50 50 0.3
Negative 78 72 0.09
Invasion
Lymphatic 67 50 0.02
Vascular/perinural 50 55 0.4
any treatment. EF dropped to 40% after the first cycle of FAC
chemotherapy. EF was maintained at 40% after radiotherapy.
Three years later, her EF was maintained at 40%. At 48 months,
her EF dropped to 30%.
For group 2. During the same follow-up period, two patients
from group 2 had lymphedema grade I (5.7%). One of them
developed cellulitis on top of lymphedema. No other events were
noticed to suggest delayed toxicities (Tables 6 and 7).
DISCUSSION
Radiotherapy in early breast cancer has been debatable for decades.
While studies had showed its role in improving loco-regional
control, its impact on OS is still unclear (13, 14).
The promising results of RT was supported by the results of
studies of Cosar et al. (15) and Ragaz et al. (8), who reported
that, addition of RT to chemotherapy for one to three node-
positive breast cancer, improved the 5-year loco-regional control,
and PFS. Further, the former study showed improvement of OS
Table 3 |The 4 year PFS for each treatment group categorized by the
prognostic factors.
Group 1% Group 2 % P -value
Age
17–<40 100 – –
40–49 75 73 0.3
50–60 70 64 0.03
61–65 60 40 0.008
Performance status
0 85 76 0.05
1 67 57 0.007
2 40 0 0.001
Pathological classification
Ductal 75 69 0.05
Lobular 63 33 0.001
Pathological grade
1 80 67 0.02
2 73 68 0.06
3 70 40 0.001
Tumor stage
pT0N1 100 50 0.001
pT1N1 70 63 0.06
pT2N1 75 57 0.003
Lymph node number
1 75 57 0.03
2 75 67 0.02
3 70 53 0.003
Her 2 neu
Positive 0 0 0.1
Negative 76 63 0.03
Invasion
Lymphatic 67 25 0.009
Vascular/perinura 60 55 0.2
by 15% at 5 years, which was found to be non-statistically sig-
nificant (p= 0.087), and the later showed improvement by 6%
at 5 years, that was as well non-statistically significant (p= 0.1)
(8, 15).
Beside these individual studies, number of systemic reviews
and metaanalyses also demonstrate an absolute survival ben-
efit of approximately 5–10% with the addition of RT (9, 14,
16, 17).
A recent metanalaysis conducted by the Early Breast-Cancer
Trialists’ Collaborative Group (EBCTCG) in women who had one
to three positive nodes. They reported that post-mastectomy RT
reduced the recurrence rate by 32% and reduced the breast-cancer
mortality rate by 20% (18).
On the other hand, an important meta-analysis by EBCTCG
(19), that included 2000 women with early breast cancer, failed to
show any improvement in OS after 20 years of follow up (19).
Many reasons can explain why the improvement in PFS was
not reflected on definite improvement in OS. Cuzik et al. (20),
reported that, there were late excess cardiac deaths that mask the
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Table 4 |The relative risk of death, and recurrence (all causes) grouped
by risk factors.
Death relative risk Recurrence relative risk
Relative risk P -value Relative risk P -value
Age
<60 1.3 0.05 1.2 0.08
>60 1.1 0.1 1.1 0.1
Performance status
<2 1 0.2 1.14 0.1
2 1.6 0.02 2 0.001
Pathological classification
Ductal 1 0.2 1 0.2
Lobular 1.1 0.09 1.9 0.01
Pathological grade
1,2 1 0.3 1.1 0.1
3 1.5 0.05 1.7 0.03
5-Tumor stage
pT0N1 1.9 0.001 1.9 0.001
pT1N1 1 0.2 1.1 0.1
pT2N1 1 0.09 1.3 0.03
Lymph node number
1 1 0.09 1.2 0.05
2, 3 1.2 0.05 1.3 0.04
Her 2 neu
Positive 1 0.4 1 0.04
Negative 1.1 0.3 1.25 0.04
Invasion
Lymphatic 1.34 0.02 2 0.001
Vascular/perinural 0.9 0.3 1.1 0.2
potential reduction in deaths from breast cancers. However, excess
cardiac deaths did not appear to be occurring in recent trials
that used modern planning techniques including CRT. This might
explain why the recent metaanalysis of EBCTCG (18), showed
clear improvement in survival (19–21).
Another clinical evidence to confirm the above point that RT
does not really increase late cardiac deaths, came from the meta-
analysis of Van de Steene et al. (14), in which they reanalyzed the
data of the EBCTCG (19) to include only recent trials, and they
showed substantial reduction in the risk of mortality associated
with radiotherapy by 12.4% (p< 0.001) (14).
Additional supporting evidence of the benefits of RT on OS
came from the hypothesis that, if the burden of distant metas-
tasis can be reduced by systemic therapy, then RT given to
the loco-regional sites might prevent secondary dissemination
(20, 21).
Finally, another evidence to support the benefit of RT on OS
came from the role of RT after breast conservative surgery. A
metaanalysis of Whelan et al. (22), showed that the addition of
RT to systemic therapy statistically significantly reduced the risk
of mortality after breast conservative surgery (odds ratio 0.83;
p= 0.04). These results had led to the general acceptance that RT
Table 5 | Characters of patients who developed locoregional
recurrence during our follow up period for each treatment group.
Group 1 Group 2
1 2 3 1 2 3 4 5 6 7
Age
17–<40
40–49 X
50–60 X X X X
61–65 X X X X X
Performance status
0 X X
1 X X X X X
2 X X X
Pathological classification
Ductal X X X X X X
Lobular X X X X
Pathological grade
1
2 X X X X
3 X X X X X X
Tumor stage
pT0N1
pT1N1 X X X X X
pT2N1 X X X X X
Lymph node number
1
2 X X X X
3 X X X X X X
Her 2 neu
Positive X X X X
Negative X X X X X X
Invasion
Lymphatic X X X X X X X
Vascular/perinural X X X
given after breast conservative surgery had favorable effects on
survival (22).
Our study included Egyptian patients with early breast can-
cer from two educational institutes in Egypt, and patients were
categorized into two groups. There was no statistical difference
between the two groups in relation to their distribution to the
pre-determined risk factors. Further, there were no ethnic or
geographical differences among the two groups. The statistical
power of the study was 0.72. Although the sample size was rel-
atively small, the power of the current trial was relatively high.
This was attributed to the high reliability, as well as the con-
trol of the confounding variables among the two groups. One
of the reasons for the relatively low sample size that, in Egypt our
breast-cancer screening program, that is supposed to detect can-
cer in early stages, is not yet well established or generalized, with
only pilot trial launched in Ismailia oncology teaching hospital in
2012/2013.
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Table 6 | Grade 3, 4 early toxicities for group 1, 2.
Side effect Group 1 Group 2
Grade 3
(%)
Grade 4
(%)
Grade 3
(%)
Grade 4
(%)
Leukoneutropenia 10 0 11 0
Anemia 2.5 0 0 0
Thrombocytopenia 2.5 0 3 0
Febrile neutropenia 5 0 3 0
Nausea, Vomiting, GIT Upset 17.5 2.5 14 0
Mucositis 15 0 11 0
Dermatitis 7.5 0 0 0
Other (discomfort, swelling) 2.5 0 0 0
Table 7 | Grade 3, four early radiotherapy related side effects and their
percentage in group 1.
Side effect Group 1
Grade 3 (%) Grade 4 (%)
Leukoneutropenia 5 0
Thrombocytopenia 0 0
Febrile neutropenia 2.5 0
Nausea, vomiting, GIT upset 10 0
Mucositis 7.5 0
Dermatitis 7.5 0
Other (discomfort, swelling) 2.5 0
Our inclusion criteria was strict to include only patients with
one to three lymph node-positive stage II breast cancer, to avoid
any other risk factors that may flaw the results.
In our study, we avoided giving RT by hypofractionation as this
approach was not standardized at time of randomization. Fur-
ther, we avoided giving radiotherapy by higher dose per fraction
that may be associated with more toxicity profile especially late
ones.
Our results indicated that, the addition of postoperative RT to
systemic therapy after mastectomy for stage II breast-cancer sig-
nificantly reduced LRR by 12.5%, and improved the PFS by 12.5%
at 4 years.
For our OS results, RT improved the OS at 4 years by 6.1%, and
that was found to be non-statistically significant. On the subgroup
analysis, RT improved OS in the high-risk group of patients who
had performance state 2, pathological grade 3, two to three positive
lymph nodes, and those with lymphatic invasion. This was found
statistically significant by univariate analysis.
The subgroup analysis for Tables 2 and 3 were done using uni-
variate analysis. Mulitvariate analysis was not feasible because of
the relatively small sample size.
Our study showed that upon recurrence, the distant metastasis
rate was the same in the two groups (20% in both). However, the
sites of metastasis were different between the two groups (Bone
group 1 and liver group 2). The significance for that, as well as the
correlation of that with RT is not yet clear.
Regarding the toxicity profile, our study confirmed that, RT
by conformal 3D radiotherapy was generally tolerated well, and
associated with mild toxicity profile.
CONCLUSION
The addition of radiotherapy to adjuvant chemotherapy in stage II
breast cancer with one to three positive lymph nodes improved the
PFS, and LRR. Radiotherapy improved OS only in patients with
high-risk features including those with PS 2, two to three positive
axillary lymph nodes, and those with lymphatic invasion.
REFERENCES
1. Salem A, Salem MA, Abbass H. Breast cancer: surgery at the south Egypt cancer
institute. Cancers (2010) 2:1771–8. doi:10.3390/cancers2041771
2. Overgaard M, Jensen MB, Overgaard J, Hansen P, Rose C, Andersson M, et al.
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients
given adjuvant tamoxifen: Danish breast cancer cooperative group DBCG 82c
trial. Lancet (1999) 353(9165):1641–8. doi:10.1016/S0140-6736(98)09201-0
3. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al.
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal
women with breast cancer. N Engl J Med (1997) 337(14):956–62. doi:10.1056/
NEJM199710023371402
4. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmas-
tectomy radiotherapy: clinical practice guidelines of the American society of
clinical oncology. J Clin Oncol (2001) 19(5):1539–69.
5. NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, Version 3.
(2014). Available from: http://www.nccn.org/professionals/physician_gls/pdf/
breast.pdf
6. Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, et al.
ACR appropriateness criteria on postmastectomy radiotherapy expert panel on
radiation oncology-breast. Int J Radiat Oncol Biol Phys (2009) 73(4):997–1002.
doi:10.1016/j.ijrobp.2008.10.080
7. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irra-
diation limited to patients with four or more positive nodes, as recommended
in international consensus reports? A subgroup analysis of the DBCG 82 b&c
randomized trials. Radiother Oncol (2007) 82(3):247–53. doi:10.1016/j.radonc.
2007.02.001
8. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locore-
gional radiation therapy in patients with high-risk breast cancer receiving adju-
vant chemotherapy: 20-year results of the British Columbia randomized trial. J
Natl Cancer Inst (2005) 97(2):116–26. doi:10.1093/jnci/dji217
9. Martin D, Dordai D, Ta˘na˘sescu R, Popa C, Grecea D, Bogdanet V, et al. CT sim-
ulation for radiotherapy in breast cancer patients. J Radiother Med Oncol (2011)
17(1):13–22.
10. Smith BD, Douglas W, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, et al.
Accelerated partial breast irradiation consensus statement from the American
society for radiation oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009)
74(4):987–1001. doi:10.1016/j.ijrobp.2009.02.031
11. Polgar C, Van Limbergen E, Potter R, Kovács G, Polo A, Lyczek J, et al.
Patient selection for accelerated partial-breast irradiation (APBI) after breast-
conserving surgery: recommendations of the groupe Européen de curiethérapie-
European society for therapeutic radiology and oncology (GEC-ESTRO) breast
cancer working group based on clinical evidence. Radiother Oncol (2010)
94(3):264–73. doi:10.1016/j.radonc.2010.01.014
12. Common Toxicity Criteria (CTC) Version 2.0. (1999). Available from: http:
//www.eortc.be/services/doc/ctc/ctcv20_4-30-992.pdf
13. Gebski V, Lagleva M, Keech A, Simes J, Langlands AO. Survival effects of post-
mastectomy adjuvant radiation therapy using biologically equivalent doses: a
clinical perspective. J Natl Cancer Inst (2006) 98:26–38. doi:10.1093/jnci/djj002
14. Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer
significantly improves overall survival: the missing link. Radiother Oncol (2000)
55:263–72. doi:10.1016/S0167-8140(00)00204-8
15. Cosar R, Uzal C, Tokatli F, Denizli B, Saynak M, Turan N, et al. Postmastectomy
irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary
lymph nodes: is there a role for radiation therapy. Radiat Oncol (2011) 6:28–35.
doi:10.1186/1748-717X-6-28
www.frontiersin.org November 2014 | Volume 4 | Article 326 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Osman et al. Adjuvant radiotherapy in early breast cancer
16. Rutqvist LE, Rose C, Cavallin-Stahl E. A systematic overview of radiation
therapy effects in breast cancer. Acta Oncol (2003) 42:532–45. doi:10.1080/
02841860310014444
17. Darby S, On behalf of the Early Breast Cancer Trialists’ Collaborative Group.
Overview of the randomised trials of radiotherapy in early breast cancer
(Abstract). Presented at the 32nd Annual San Antonio Breast Cancer Symposium.
San Antonio, TX (2009).
18. McGale P, Taylor C, Correa C, On behalf of the Early Breast Cancer Trialists’ Col-
laborative Group. Effect of radiotherapy after mastectomy and axillary surgery
on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of
individual patient data for 8135 women in 22 randomised trials. Lancet (2014)
383(9935):2127–35. doi:10.1016/S0140-6736(14)60488-8
19. EBCTCG. Favourable and unfavourable effects on long term survival of radio-
therapy for early breast cancer; an overview of the randomized trials. Lancet
(2000) 355:757–70.
20. Cuzik J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause
specific mortality in long term survivors of breast cancer who participated in
trials of radiotherapy. J Clin Oncol (1994) 12:447–53.
21. Krauss DJ, Kestin LL, Raff G, Yan D, Wong J, Gentry R, et al. MRI-based volu-
metric assessment of cardiac anatomy and dose reduction via active breathing
control during irradiation for left-sided breast cancer. Int J Radiat Oncol Biol
Phys (2005) 61:1243–50. doi:10.1016/j.ijrobp.2004.10.012
22. Whelan TJ, Julian J, Wright J. Does radiation therapy improve survival in breast
cancer? A Meta-analysis. J Clin Oncol (2000) 18:1220–9.
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 19 September 2014; accepted: 30 October 2014; published online: 19
November 2014.
Citation: Osman MAM, Elkady MS and Nasr KE (2014) For stage II node-positive
breast cancer, is it worthwhile to consider adjuvant radiotherapy followingmastectomy?
Front. Oncol. 4:326. doi: 10.3389/fonc.2014.00326
This article was submitted to Radiation Oncology, a section of the journal Frontiers in
Oncology.
Copyright © 2014 Osman, Elkady and Nasr. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Oncology | Radiation Oncology November 2014 | Volume 4 | Article 326 | 8
